Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Noel, Marcus

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. [electronic resource] - Investigational new drugs 06 2020 - 800-811 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1573-0646

10.1007/s10637-019-00830-3 doi


Adenocarcinoma--drug therapy
Aged
Albumins--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Pancreatic Ductal--drug therapy
Chemokine CCL2--antagonists & inhibitors
Cohort Studies
Deoxycytidine--analogs & derivatives
Female
Humans
Male
Middle Aged
Paclitaxel--therapeutic use
Pancreatic Neoplasms--drug therapy
Prognosis
Pyrrolidines--therapeutic use
Small Molecule Libraries--therapeutic use
Tumor Microenvironment--drug effects
Gemcitabine